Extended Data Fig. 3: Kaplan-Meier plots of disease-free and overall survival for responders versus nonresponders. | Nature Medicine

Extended Data Fig. 3: Kaplan-Meier plots of disease-free and overall survival for responders versus nonresponders.

From: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial

Extended Data Fig. 3: Kaplan-Meier plots of disease-free and overall survival for responders versus nonresponders.The alternative text for this image may have been generated using AI.

a, DFS for pMMR pathologic responders (blue) versus dMMR pathologic responders (green) versus pMMR pathologic nonresponders (red). b, Overall survival (OS) for pathologic responders (red) versus nonresponders (blue). c, OS for pMMR pathologic responders (blue) versus dMMR pathologic responders (green) versus pMMR pathologic nonresponders (red).

Back to article page